Technical discussion to define a vaccination strategy with the Jynneos vaccine against Mpox: Recommendation for vaccination with Jynneos vaccine for the following groups: 1) Pre-exposure vaccination: People living with HIV/AIDS: cisgender men, transvestites, and transgender women; aged 18 years or older; and with immune status identified by CD4 T lymphocyte count less than 200 cells in the past six months. Laboratory professionals working directly with Orthopoxviruses in biosafety level 3 (NB-3) laboratories, 18 to 49 years of age. 2) Post-exposure: people who have had direct contact with body fluids and secretions of people suspected, probable or confirmed to have mpox, whose exposure is classified as high or medium risk. Details on the operationalization of vaccination will be discussed with the technical areas of the PNI/MS, as well as the preparation of the technical report.